Aileron Therapeutics, Inc. (ALRN)

NASDAQ: ALRN · Delayed Price · USD
0.490
-0.003 (-0.55%)
At close: Jan 14, 2022 4:00 PM
0.510
0.020 (4.145%)
After-hours:Jan 14, 2022 7:21 PM EST

Company Description

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States.

The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.

Aileron Therapeutics, Inc. has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC.

The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.

Aileron Therapeutics, Inc.
CountryUnited States
Founded2001
IPO DateJun 29, 2017
IndustryBiotechnology
SectorHealth Care
Employees8

Contact Details

Address:
285 Summer Street
Boston, MA 02210
United States
Phone617 995 0900
Websiteaileronrx.com

Stock Details

Ticker SymbolALRN
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001420565

Key Executives

NamePosition
Dr. Manuel C. AivadoPresident, Chief Executive Officer and Director
Richard J. Wanstall M.B.A.SVice President, Chief Financial Officer and Treasurer
Dr. Vojislav Vukovic M.D., Ph.D.Senior Vice President and Chief Medical Officer
Dr. D. Allen Annis Ph.D.Senior Vice President of Research

Latest SEC Filings

DateTypeTitle
Jan 5, 20228-KCurrent report
Dec 7, 20218-KCurrent report
Nov 12, 202110-QQuarterly report [Sections 13 or 15(d)]
Sep 17, 20218-KCurrent report
Sep 13, 20218-KCurrent report
Aug 11, 2021S-8Securities to be offered to employees in employee benefit plans
Aug 11, 202110-QQuarterly report [Sections 13 or 15(d)]
Jul 1, 20218-KCurrent report
Jun 17, 20214Statement of changes in beneficial ownership of securities
Jun 17, 20214Statement of changes in beneficial ownership of securities
View All SEC Filings